Table 2.
ProBNP1-108 | BNP32 | |||||
---|---|---|---|---|---|---|
HR, Tertile 2 vs 1 (95% CI)§ | HR, Tertile 3 vs 1 (95% CI)§ | HR per 2-fold increase in proBNP1-108 (95% CI) | HR, Tertile 2 vs 1 (95% CI)§ | HR, Tertile 3 vs 1 (95% CI)§ | HR per 2-fold increase in BNP1-32 (95% CI) | |
Unadjusted | 5.6 (3.0–10.4) | 10.1 (5.5–18.4) | 1.5 (1.3–1.6) | 3.2 (1.9–5.6) | 7.6 (4.6–12.7) | 1.5 (1.4–1.6) |
Model 1* | 5.7 (2.9–10.8) | 9.5 (5.0–18.0) | 1.4 (1.3–1.6) | 3.2 (1.8–5.7) | 6.9 (4.0–11.8) | 1.4 (1.3–1.6) |
Model 2† | 5.0 (2.6–9.7) | 7.8 (4.0–15.4) | 1.4 (1.3–1.5) | 2.9 (1.6–5.2) | 5.5 (3.1–9.8) | 1.4 (1.3–1.5) |
Model 3‡ | 3.9 (2.0–7.7) | 4.9 (2.5–9.7) | 1.3 (1.2–1.4) | 2.5 (1.4–4.4) | 3.6 (2.0–6.4) | 1.3 (1.2–1.4) |
Model 1 adjusted for age, sex, race, tobacco, creatinine, body mass index
Model 2 adjusted for Model 1 + EF + cardiomyopathy etiology (ischemic versus non-ischemic)
Model 3 adjusted for Model 2 + NYHA Class (I/II versus III/IV)
all p<0.001, including test for trend